Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 3 → 6 locations
    • Interventions: Durvalumab 50 MG/ML (Drug) to Durvalumab 50 MG/ML (Drug)
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Study sites: 1 to 3
    • Start date changed from estimate of Feb 2026 to Feb 12, 2026
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 2027 to Feb 2029
    • Study sites: 0 to 1
    • Study completion date: Jul 2030 to Feb 2031
    v3
  4. Start date: Sep 2025 to Feb 2026v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Trial Details
NCT Number NCT07149363
Lead Sponsor Alliance Foundation Trials, LLC.
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Small Cell Lung Cancer (SCLC)
Related terms Small Cell Lung Carcinoma
Enrollment 65 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov